Effects of Non-alcoholic Beer in Patients With Type 2 Diabetes
DIABEER
1 other identifier
interventional
30
1 country
1
Brief Summary
The aim of the study is to investigate the effects of non-alcoholic beer in patients with type 2 diabetes. Subjects will be divided into two groups: the control group, where participants will be consuming a bottle of water (330ml) every day for 12 weeks, and the intervention group, where participants will be consuming a bottle of non-alcoholic beer (330ml) for the same period.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable diabetes-mellitus-type-2
Started Nov 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 7, 2018
CompletedFirst Submitted
Initial submission to the registry
November 15, 2018
CompletedFirst Posted
Study publicly available on registry
November 19, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2019
CompletedJanuary 29, 2019
October 1, 2018
8 months
November 15, 2018
January 25, 2019
Conditions
Outcome Measures
Primary Outcomes (5)
Changes in fasting capillary blood glucose from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Changes in fasting insulin levels from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Changes in HOMA-IR from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Changes in HOMA-B from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Changes in HbA1c levels from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Secondary Outcomes (7)
Changes in intestinal microbiota from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Changes in body mass index from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Changes in total body fat mass from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Changes in fasting serum total cholesterol from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
Changes in fasting serum high-density lipoprotein (HDL) cholesterol from baseline to visit 2 and 3
at visit 1 (after 1-week run-in period), visit 2 (after 6-week intake period), visit 3 (after 12-week intake period)
- +2 more secondary outcomes
Study Arms (2)
Control Group
PLACEBO COMPARATORParticipants will consume a bottle of water (330 ml) every day for 12 weeks.
Non-alcoholic beer
EXPERIMENTALParticipants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
Interventions
Participants will consume a bottle of water (330 ml) every day for 12 weeks.
Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
Eligibility Criteria
You may qualify if:
- Men and women diagnosed with type 2 diabetes mellitus, according to the American Diabetes Association criteria;
- Ages 40-80 years;
- Non-smoker;
- Willing and able to provide written informed consent.
You may not qualify if:
- Changes in oral glycaemic-control medications in the last 3 months;
- Subjects with HbA1c levels under 6.4% or above 10%;
- Subjects under insulinotherapy;
- Subjects with triglycerides levels above 4.52 nmol/L(400 mg/dL);
- Intake of antibiotics in the last 12 weeks;
- Subjects not willing to avoid drinking beer during the study;
- Subjects with a diagnosis of any digestive disease including functional bowel disorders such as IBS;
- Pregnant women or women planning to become pregnant during the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Universidade do Portolead
- Center for Health Technology and Services Researchcollaborator
- NOVA Medical Schoolcollaborator
Study Sites (1)
NOVA Medical School, NOVA University of Lisbon
Lisbon, 1169-056, Portugal
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 15, 2018
First Posted
November 19, 2018
Study Start
November 7, 2018
Primary Completion
July 1, 2019
Study Completion
December 1, 2019
Last Updated
January 29, 2019
Record last verified: 2018-10